Journal of the Korean Medical Association (대한의사협회지)

Korean Medical Association (대한의사협회)
권호 표지

Novel Pharmacotherapies for Alzheimer's Disease

알츠하이머병의 새로운 약물치료

  • Han, Seol-Heui (Department of Neurology, Konkuk University School of Medicine, Novel Pharmacotherapies for Alzheimer's Disease)
  • 한설희 (건국의학전문대학원 신경과, 건국대 노인성신경질환연구센터)
  • Published : 2009.11.10

⟨ Previous Next ⟩

Abstract

Alzheimer disease (AD) is pathologically characterized by extracellular amyloid deposits composed of beta-amyloid (A${\beta}$) peptide, neurofibrillary tangles (NFTs) made up of hyperphosphorylated tau, and deficit of cholinergic neurons in the basal forebrain. It is the most common neurodegenerative disease in the elderly. With the aging of the population, the incidence and prevalence of AD will also increase rapidly. The subsequent growing socioeconomic burden seems to be inevitable until effective therapeutic strategies are developed. Currently available treatments approved by the US Food and Drug Administration, while ameliorating the symptoms, do not halt progression or cure the illness. AD is a multifactorial syndrome with several target proteins contributing to its etiology. In this review, various small molecules targeting pathological hall marks or their major constituents that have been reported in the literature will be discussed, with emphasis on compounds that are presently being investigated in clinical trials.

Keywords

References

  1. Vetrivel KS, Thinakaran G. Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments. Neurology 2006; 66: S69-73.
  2. Lee VM, Trojanowski JQ. Mechanisms of parkinson's disease linked to pathological alpha-synuclein: New targets for drug discovery. Neuron 2006; 52: 33-38. https://doi.org/10.1016/j.neuron.2006.09.026
  3. Roberson MR, Harrell LE. Cholinergic activity and amyloid precursor protein metabolism. Brain Res Brain Res Rev 1997; 25: 50-69. https://doi.org/10.1016/S0165-0173(97)00016-7
  4. Roberson MR, Kolasa K, Parsons DS, Harrell LE. Cholinergic denervation and sympathetic ingrowth result in persistent changes in hippocampal muscarinic receptors. Neuroscience 1997; 80: 413-418. https://doi.org/10.1016/S0306-4522(97)00153-X
  5. Bartolini M, Bertucci C, Cavrini V, Andrisano V. Beta-amyloid aggregation induced by human acetylcholinesterase: Inhibition studies. Biochem Pharmacol 2003; 65: 407-416. https://doi.org/10.1016/S0006-2952(02)01514-9
  6. De Ferrari GV, Canales MA, Shin I, Weiner LM, Silman I, Inestrosa NC. A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry 2001; 40: 10447-10457. https://doi.org/10.1021/bi0101392
  7. Hardy J. Molecular genetics of alzheimer's disease. Acta Neurol Scand Suppl 1996; 165: 13-17.
  8. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al. Cloning of a gene bearing missense mutations in early-onset familial alzheimer's disease. Nature 1995; 375: 754-760. https://doi.org/10.1038/375754a0
  9. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T, et al. Familial alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the alzheimer's disease type 3 gene. Nature 1995; 376: 775-778. https://doi.org/10.1038/376775a0
  10. Hardy J. Alzheimer's disease: The amyloid cascade hypothesis: An update and reappraisal. J Alzheimers Dis 2006; 9: 151-153. https://doi.org/10.3233/JAD-2006-9S317
  11. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-842. https://doi.org/10.1038/nm1782
  12. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-539. https://doi.org/10.1038/416535a
  13. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002; 298: 789-791. https://doi.org/10.1126/science.1074069
  14. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional charac-terization of alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005; 25: 7709-7717. https://doi.org/10.1523/JNEUROSCI.2177-05.2005
  15. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. Beta-secretase protein and activity are increased in the neocortex in alzheimer disease. Arch Neurol 2002; 59: 1381-1389. https://doi.org/10.1001/archneur.59.9.1381
  16. Holtzman DM. Amyloid-beta binding molecule: Potential role in the pathogenesis and treatment of alzheimer disease. Alzheimer Dis Assoc Disord 2003; 17(Suppl 2): S66-68. https://doi.org/10.1097/00002093-200304002-00011
  17. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of alzheimer disease and relation to apolipoprotein e genotype. Arch Neurol 1998; 55: 937-945. https://doi.org/10.1001/archneur.55.7.937
  18. Asai M, Hattori C, Iwata N, Saido TC, Sasagawa N, Szabo B, Hashimoto Y, Maruyama K, Tanuma S, Kiso Y, Ishiura S. The novel beta-secretase inhibitor kmi-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem 2006; 96: 533-540. https://doi.org/10.1111/j.1471-4159.2005.03576.x
  19. Stachel SJ. Progress toward the development of a viable BACE-1 inhibitor. Drug Develop Research 2009; 70: 101-110. https://doi.org/10.1002/ddr.20289
  20. Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. Reconstitution of gamma-secretase activity. Nat Cell Biol 2003; 5: 486-488. https://doi.org/10.1038/ncb960
  21. Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Skeletal and cns defects in presenilin-1-deficient mice. Cell 1997; 89: 629-639. https://doi.org/10.1016/S0092-8674(00)80244-5
  22. Wu WL, Zhang L. Gamma -secretase Inhibitors for the treatment of Alzheimer's disease. Drug Develop Resear 2000; 70: 94-100.
  23. Bell KF, Claudio Cuello A. Altered synaptic function in alzheimer's disease. Eur J Pharmacol 2006; 545: 11-21. https://doi.org/10.1016/j.ejphar.2006.06.045
  24. Sekino Y, Kojima N, Shirao T. Role of actin cytoskeleton in dendritic spine morphogenesis. Neurochem Int 2007; 51: 92-104. https://doi.org/10.1016/j.neuint.2007.04.029
  25. Zhou Y, Su Y, Li B, Liu F, Ryder JW, Wu X, Gonzalez-DeWhitt PA, Gelfanova V, Hale JE, May PC, Paul SM, Ni B. Non-steroidal anti-inflammatory drugs can lower amyloidogenic abeta42 by inhibiting rho. Science 2003; 302: 1215-1217. https://doi.org/10.1126/science.1090154
  26. Tjernberg LO, Naslund J, Lindqvist F, Johansson J, Karlstrom AR, Thyberg J, Terenius L, Nordstedt C. Arrest of betaamyloid fibril formation by a pentapeptide ligand. J Biol Chem 1996; 271: 8545-8548. https://doi.org/10.1074/jbc.271.15.8545
  27. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for alzheimer's therapy. Nat Med 1998; 4: 822-826. https://doi.org/10.1038/nm0798-822
  28. Hughes E, Burke RM, Doig AJ. Inhibition of toxicity in the beta-amyloid peptide fragment beta-(25-35) using n-methylated derivatives: A general strategy to prevent amyloid formation. J Biol Chem 2000; 275: 25109-25115. https://doi.org/10.1074/jbc.M003554200
  29. Bush AI. The metallobiology of alzheimer's disease. Trends Neurosci 2003; 26: 207-214. https://doi.org/10.1016/S0166-2236(03)00067-5
  30. White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, Hoke DE, Holsinger RM, Evin G, Cherny RA, Hill AF, Barnham KJ, Li QX, Bush AI, Masters CL. Degradation of the alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem 2006; 281: 17670-17680. https://doi.org/10.1074/jbc.M602487200
  31. Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: A review of their intracellular targets. Eur J Pharmacol 2006; 545: 51-64. https://doi.org/10.1016/j.ejphar.2006.06.025
  32. Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, Cole GM. Phenolic anti-inflammatory antioxidant reversal of abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 2001; 22: 993-1005. https://doi.org/10.1016/S0197-4580(01)00300-1
  33. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human alzheimer disease after immunization with amyloid-beta peptide: A case report. Nat Med 2003; 9: 448-452. https://doi.org/10.1038/nm840
  34. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA. Long-term effects of abeta42 immunisation in alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216-223. https://doi.org/10.1016/S0140-6736(08)61075-2
  35. Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, Tompkins C, Leibman C, Pomfret M, Grundman M. Longterm follow-up of patients immunized with an1792: Reduced functional decline in antibody responders. Curr Alzheimer Res 2009; 6: 144-151 https://doi.org/10.2174/156720509787602852
  36. Relkin NR. Beyond symptomatic therapy: A re-examination of acetylcholinesterase inhibitors in alzheimer's disease. Expert Rev Neurother 2007; 7: 735-748. https://doi.org/10.1586/14737175.7.6.735
  37. Giri R, Shen Y, Stins M, Du Yan S, Schmidt AM, Stern D, Kim KS, Zlokovic B, Kalra VK. Beta-amyloid-induced migration of monocytes across human brain endothelial cells involves rage and pecam-1. Am J Physiol Cell Physiol 2000; 279: C1772-1781. https://doi.org/10.1152/ajpcell.2000.279.6.C1772
  38. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV. Clearance of alzheimer's amyloid-ss (1-40) peptide from brain by ldl receptor-related protein-1 at the bloodbrain barrier. J Clin Invest 2000; 106: 1489-1499. https://doi.org/10.1172/JCI10498
  39. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, Goate A, Mayo K, Perlmutter D, Coma M, Zhong Z, Zlokovic BV. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 2007; 13: 1029-1031. https://doi.org/10.1038/nm1635
  40. Guan H, Liu Y, Daily A, Police S, Kim MH, Oddo S, LaFerla FM, Pauly JR, Murphy MP, Hersh LB. Peripherally expressed neprilysin reduces brain amyloid burden: A novel approach for treating alzheimer's disease. J Neurosci Res 2009; 87: 1462-1473. https://doi.org/10.1002/jnr.21944
  41. Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, Tanzi RE, Selkoe DJ. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol 2004; 164: 1425-1434. https://doi.org/10.1016/S0002-9440(10)63229-4
  42. Nalivaeva NN, Fisk LR, Belyaev ND, Turner AJ. Amyloiddegrading enzymes as therapeutic targets in alzheimer's disease. Curr Alzheimer Res 2008; 5: 212-224. https://doi.org/10.2174/156720508783954785
  43. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JB, Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, van Swieten J, Mann D, Lynch T, Heutink P. Association of missense and 5'-splice-site mutations in tau with the inherited dementia ftdp-17. Nature 1998; 393: 702-705. https://doi.org/10.1038/31508
  44. Savage MJ, Gingrich DE. Advances in the development of kinase inhibitor therapeutics for Alzheimer's disease. Drug Deveop Res 2009; 70: 125-144. https://doi.org/10.1002/ddr.20287
  45. Sigurdsson EM. Immunotherapy targeting pathological tau protein in alzheimer's disease and related tauopathies. J Alzheimers Dis 2008; 15: 157-168. https://doi.org/10.3233/JAD-2008-15202
  46. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate alzheimer's disease: A randomised, double-blind, placebo-controlled study. Lancet 2008; 372: 207-215. https://doi.org/10.1016/S0140-6736(08)61074-0